Hanmi Pharmaceutical newly included in the DJSI Korea Sustainability Index

Hanmi Pharmaceutical has been newly included in the “2024 Dow Jones Sustainability Indices (DJSI) Korea Index” in recognition of its ESG management performance.

The DJSI is a sustainability index published annually by S&P Global, the world's largest financial information provider. It is globally recognized for its comprehensive evaluation of ESG factors and company economic performance.

It is widely used as a benchmark to help investors make responsible investment decisions.

In the DJSI Korea Index, only companies ranked in the top 30 percent of the 200 largest domestic companies by floating market capitalization are eligible for inclusion. Hanmi Pharmaceutical was included for the first time in the index due to its environmental policy and climate strategy, quality management, occupational health and safety, and business ethics.

Hanmi Pharmaceutical operates an hEHS Committee comprised of representatives from all five business sites, led by its CEO, to lead environmental management in achieving carbon neutrality and responding to climate change. The committee is the first EHS (environment, health, and safety) organization established in the Korean pharmaceutical industry in 2019. It establishes strategies by period to realize carbon neutrality and minimize environmental impact.

Besides, Hanmi Pharmaceutical continuously identifies and improves environmental issues that may arise in production. In 2012, the company introduced an environmental management system (ISO 14001) and is building a global-level environmental management system to minimize environmental pollution and negative impacts.

In 2007, Hanmi introduced the Compliance Program (CP), a voluntary compliance system to comply with fair trade laws and regulations, for the first time in the pharmaceutical industry. Hanmi was also the first Korean company to receive the highest CP rating of AAA from the Fair Trade Commission and has maintained it for the longest period, demonstrating its excellence in ethical management.

Hanmi Pharmaceutical has received integrated certification for its anti-corruption management system (ISO 37001) and compliance management system (ISO 37301) from the Korea Compliance Institute (KCI). It also has received numerous government awards for contributing to the spread of CP culture as a model company for ethical management based on fair trade and win-win.

“Our company-wide efforts for sustainable management have borne fruit and resulted in our inclusion in the DJSI Korea Index,” Hanmi Pharmaceutical CEO Park Jae-hyun said. “We will continue to enhance communication with various stakeholders and fulfill our corporate social roles and responsibilities to increase our corporate value further.”